Clinical Trial Update: First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating first-line furmonertinib in advanced non-small cell lung cancer with EGFR uncommon mutations (G719X, L861Q, S768I).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Chongqing University Cancer Hospital | Conditions: Non-small Cell Lung Cancer, EGFR G719X | Phase 2 | Status: UNKNOWN